Passa al contenuto
Merck

Vai a

D3821

Devazepide

≥98% (HPLC), powder

Sinonimo/i:

(S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide, L-364,718, MK 329

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
A voi/SKUDisponibilitàPrezzo
5 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 205.00
25 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 746.00
CHF 634.10

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C25H20N4O2
Numero CAS:
Peso molecolare:
408.45
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

CHF 205.00


Per conoscere la disponibilità, visualizza il carrello

Richiedi un ordine in blocco
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti


Quality Segment

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to off-white

solubility

DMSO: >5 mg/mL

originator

Merck & Co., Inc., Kenilworth, NJ, U.S.

storage temp.

2-8°C

SMILES string

CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15

InChI

1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1

InChI key

NFHRQQKPEBFUJK-HSZRJFAPSA-N

General description

Devazepide is derived from asperlicin by chemical modification and has the benzodiazepine backbone.

Application

Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells and in human pancreatic slices.

Biochem/physiol Actions

Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine.
Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.
Devazepide is a CCK1 receptor antagonist.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
SML2883SML2984SML1984
Devazepide ≥98% (HPLC), powder

Sigma-Aldrich

D3821

Devazepide

Paquinimod ≥98% (HPLC)

Sigma-Aldrich

SML2883

Paquinimod

BIX02188 ≥98% (HPLC)

Sigma-Aldrich

SML2984

BIX02188

GSK9311 ≥98% (HPLC)

Sigma-Aldrich

SML1984

GSK9311

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

-

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

−20°C

solubility

DMSO: >5 mg/mL

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear (warmed)

storage condition

desiccated

storage condition

-

storage condition

-

storage condition

-


pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 1 Oral

Classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti



Questions

Reviews

No rating value

Active Filters